Log In Get Started
Press Releases May 13, 2026 07:00 AM

Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Sagimet Biosciences to Present at H.C. Wainwright Annual BioConnect Investor Conference at NASDAQ

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
SGMT

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company focused on developing novel FASN inhibitors for metabolic and fibrotic diseases, announced its participation in the H.C. Wainwright 4th Annual BioConnect Investor Conference with a fireside chat scheduled on May 19, 2026. The event will be webcast and archived for investors and media.

Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
SGMT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Sagimet is developing first-in-class FASN inhibitors targeting dysfunctional metabolic and fibrotic pathways.
  • The company is addressing unmet medical needs in diseases linked to fatty acid overproduction, including acne, MASH, and certain tumors.
  • Participation in the H.C. Wainwright BioConnect conference provides an investor platform to discuss pipeline and corporate strategy.

SAN MATEO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026, in New York, NY with a fireside chat at 2pm ET (link here).

A webcast of the fireside chat will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com, with an archived replay available for 90 days following the live event.

About Sagimet Biosciences 

Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, and a key pathway implicated in multiple diseases, such as acne, MASH and certain FASN-dependent tumor types. For additional information about Sagimet, please visit www.sagimet.com.

Investor Contact:
Joyce Allaire 
LifeSci Advisors 
[email protected]

Media Contact:
Maggie Whitney
LifeSci Communications
[email protected]


Risks

  • As a clinical-stage biopharmaceutical company, Sagimet's products are still under development and may face regulatory or clinical trial risks.
  • Market acceptance and commercial viability of FASN inhibitors remain uncertain, impacting long-term financial prospects.
  • The competitive landscape in metabolic and fibrotic disease therapeutics may pose challenges to Sagimet's future growth.

More from Press Releases

Fervo Energy Learning Curve Continues on 3rd Generation Well Design, Boosting Drilling Rates by 143% Since Its First Cape Station Well Jul 8, 2026 Columbus Circle Capital Corp III Announces Pricing of $200,000,000 Initial Public Offering Jul 8, 2026 Mercator Acquisition Corp. Announces Pricing of $150 Million Initial Public Offering Jul 8, 2026 Teck to Release Second Quarter 2026 Results on July 23, 2026 Jul 8, 2026 Both Leading Independent Proxy Advisors Recommend Aterian Stockholders Vote for the Asset Sale Jul 8, 2026